Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept plus methotrexate versus methotrexate in early erosive rheumatoid arthritis (Phase IIIB)
2005-000784-26Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2005
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of abatacept in rheumatoid arthritis (RA) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: ACR50 response at month 12. Started Jul 2005; status: completed.
02
Drugs
abatacept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2005-000784-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000784-26.